ArticleFrontiers in immunology2026
Renshen-Baidu-San restores epithelial-immune crosstalk and drives type 2 immune repair in ulcerative colitis: an integrated multi-omics study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa characterized by recurrent flares and difficulty achieving sustained remission. Renshen-Baidu-San (BDS), a classical Chinese herbal prescription, has shown promising clinical benefit in relieving UC symptoms, but its underlying therapeutic mechanisms remain insufficiently defined. This study aimed to elucidate the multiple biological mechanisms underlying the therapeutic effects of BDS in UC. Methods: We utilized an integrated multi-omics and experimental approach, combining serum metabolomics, pharmacological network analysis, molecular docking, and single-cell RNA sequencing in a DSS-induced UC mouse model, supplemented by colon organoid experiments. Key findings were validated using histopathology, immunohistochemistry, immunofluorescence, quantitative RT-PCR, ELISA, and flow cytometry. Results: Serum metabolomics demonstrated that BDS modulates steroid- and lipid-derived metabolites, thereby influencing steroid hormone biosynthesis, bile acid turnover, and lipid pathways including arachidonic acid and linoleic acid metabolism. Network pharmacology based on serum-detected components further highlighted BDS's regulatory effects on inflammatory signaling and cellular proliferation, while molecular docking identified stable and favorable protein-ligand interactions. Single-cell transcriptomics revealed that BDS corrected UC-induced epithelial-immune dysregulation, with Tuft and T-1 cell subclusters emerging as key responders through coordinated suppression of NF-κB-driven TNF-α signaling; ligand-receptor analysis indicated restoration of epithelial-immune communication. Colon organoid experiments corroborated mucosal repair, crypt structural recovery, Tuft cell expansion, and a shift toward a tissue-restorative type 2 immune profile, characterized by elevated IL-4 and IL-25 and reduced IL-13. Conclusion: Our findings indicate that BDS treatment in DSS-induced colitis is accompanied by alterations in metabolic pathways, epithelial-immune communication, and cell-type-specific transcriptional programs, which may be relevant to type 2 immune-mediated mucosal repair processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.